This Combined Synopsis/Solicitation opportunity from Department Of Defense was posted on October 18, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
INTERCEPT Blood System Platelet Processing and ILLUMINATOR Service Maintenance
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The contract outlined in the notice intends to award a sole source supply contract to Cerus Corporation for the provision of INTERCEPT Platelet Small Volume Processing Sets, INTERCEPT Platelet Processing Sets with Dual Storage Containers, and annual maintenance for specific Illuminator serial numbers in support of the Blood Bank Department at the Naval Hospital Guam. This action is based on the determination that only one source can meet the government's needs, as per the Federal Acquisition Regulation. The contract will be a firm fixed price agreement starting from December 1, 2024, with option years extending through November 30, 2027. Cerus Corporation is recognized for its expertise in pathogen reduction technology, having developed the FDA-approved INTERCEPT Blood System that enhances blood safety by significantly reducing the risks associated with transfusions. The company will be required to submit a capability statement, detailing their management and technical abilities, to demonstrate compliance with the contract specifications. Interested parties can challenge this sole source determination, but such challenges must be submitted by the specified deadline, and general inquiries will not be deemed substantive responses. Communication regarding this opportunity is directed strictly via email, emphasizing the importance of formal submissions.
General Info
Contract Value
$128,498Place of Performance
Agana Heights, GU, 96910, USASet-Aside
Awardee
CERUS CORPORATIONAward Issued Date
Documents
3AI Contract Breakdown
Uniform Contract FormatContract not broken down yet
CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.
Timeline
Submission Closed
Organization & Contact Information
Full Description
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to award a firm fixed price contract for INTERCEPT Platelet Small Volume Processing Set, INTERCEPT Platelet Processing Set with Dual Storage Containers, and Annual Maintenance for Illuminator Serial Numbers V02081701 and V0281702 in support of Blood Bank Department, Naval Hospital Guam in accordance with Federal Acquisition Regulation FAR 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to:
Cerus Corporation
Unique Entity ID: KJJQRRLY2FL5
CAGE: 1PVJ6
1220 Concord Ave., Ste 600
Concord, CA 94520-4906
Period of Performance:
Base: 12/1/2024 – 11/30/2025
Option 1: 12/1/2025 – 11/30/2026
Option 2: 12/1/2026 – 11/30/2027
Cerus Corporation is a leading biotechnology company specializing in pathogen reduction technology for blood products. Their INTERCEPT Blood System is FDA approved for use with apheresis platelets and whole blood-derived plasma, significantly reducing the risk of transfusion-transmitted infections (TTIs) and sepsis. The system allows for the production of therapeutic platelet doses and plasma units, enhancing blood safety. Cerus Corporation holds exclusive licensing agreements and has a proven track record of providing highly specialized services that are critical for maintaining blood safety standards. Their unique qualifications make them the ideal choice for fulfilling the contract requirements.
This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required product for United States Naval Hospital Guam. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.
If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Merlinda M. Labaco at contact@example.gov. The closing date for challenges is no later than 1:00 pm Pacific Daylight Time, 4 November 2024.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED
More opportunities from Department Of Defense → DEFENSE HEALTH AGENCY (DHA)
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
